Spanish dermatology specialist Almirall (BME: ALM) and etherna, a privately-held Belgian mRNA/lipid nanoparticle (LNP) technology platform company, have announc 12 December 2023
Two subsidiaries of Connect Biopharma are to work together with Simcere Pharmaceutical on the development of rademikibart in China, Hong Kong, Macau and Taiwan. 22 November 2023
Almirall has won European Commission (EC) approval for Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients with moderate-to-severe atopic 17 November 2023
Spanish dermatology specialist Almirall and US generative AI drug creation company Absci Corporation have announced a drug discovery partnership. 14 November 2023
Aclaris Therapeutics stock has taken a battering again, after the Phase IIb ATI-450-RA-202 trial was found to have missed its primary and secondary endpoints. 14 November 2023
Swiss pharma major Novartis (NOVN: VX) has secured another approval from the US regulator for Cosentyx (secukinumab), a biologic which blocks the IL-17A cytokin 1 November 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.